An official website of the United States government
Bacterial and Fungal Infections in Persons Who Inject Drugs — Western New York, 2017
Weekly / July 5, 2019 / 68(26);583–586
Kathleen P. Hartnett, PhD1,2; Kelly A. Jackson, MPH2; Christina Felsen, MPH3; Robert McDonald, MD1,4; Ana Cecilia Bardossy, MD1,2; Runa H. Gokhale, MD2; Ian Kracalik, PhD1,2; Todd Lucas, MD1,2; Olivia McGovern, PhD1,5; Chris A. Van Beneden, MD5; Michael Mendoza, MD6; Michele Bohm, MPH7; John T. Brooks, MD8; Alice K. Asher, PhD9; Shelley S. Magill, MD, PhD2; Anthony Fiore, MD2; Debra Blog, MD4; Elizabeth M. Dufort, MD4; Isaac See, MD2; Ghinwa Dumyati, MD3 (View author affiliations)
View suggested citationSummary
What is already known about this topic?
Bacterial and fungal infections among persons who inject drugs are increasing.
What is added by this report?
Among a sample of persons in western New York who inject drugs and were hospitalized or treated in the emergency department for a bacterial and fungal infection, Staphylococcus aureus was the most common pathogen. Nearly all persons with such infections injected opioids; most were not offered medication-assisted treatment to reduce injection drug use.
What are the implications for public health practice?
Health care visits for bacterial and fungal infections represent an opportunity to treat the underlying opioid use disorder with medication-assisted treatment. Because many infections are caused by skin flora such as S. aureus, injecting without first cleaning the injection site and washing hands increases the risk for bacterial and fungal infections.
During 2014–2017, CDC Emerging Infections Program surveillance data reported that the occurrence of invasive methicillin-resistant Staphylococcus aureus (MRSA) infections associated with injection drug use doubled among persons aged 18–49 years residing in Monroe County in western New York.* Unpublished surveillance data also indicate that an increasing proportion of all Candida spp. bloodstream infections in Monroe County and invasive group A Streptococcus (GAS) infections in 15 New York counties are also occurring among persons who inject drugs. In addition, across six surveillance sites nationwide, the proportion of invasive MRSA infections that occurred in persons who inject drugs increased from 4.1% of invasive MRSA cases in 2011 to 9.2% in 2016 (1). To better understand the types and frequency of these infections and identify prevention opportunities, CDC and public health partners conducted a rapid assessment of bacterial and fungal infections among persons who inject drugs in western New York. The goals were to assess which bacterial and fungal pathogens most often cause infections in persons who inject drugs, what proportion of persons who inject use opioids, and of these, how many were offered medication-assisted treatment for opioid use disorder. Medication-assisted treatment, which includes use of medications such as buprenorphine, methadone, and naltrexone, reduces cravings and has been reported to lower the risk for overdose death and all-cause mortality in persons who use opioids (2,3). In this assessment, nearly all persons with infections who injected drugs used opioids (97%), but half of inpatients (22 of 44) and 12 of 13 patients seen only in the emergency department (ED) were not offered medication-assisted treatment. The most commonly identified pathogen was S. aureus (80%), which is frequently found on skin. Health care visits for bacterial and fungal infections associated with injection opioid use are an opportunity to treat the underlying opioid use disorder with medication-assisted treatment. Routine care for patients who continue to inject should include advice on hand hygiene and not injecting into skin that has not been cleaned or to use any equipment contaminated by reuse, saliva, soil, or water (4,5).
The team obtained and reviewed records for hospital admissions and ED visits during April 1–June 30, 2017, from a convenience sample of five hospitals in western New York. Patients of any age who had 1) positive cultures for S. aureus (excluding nasal specimens), Candida spp. in blood, or GAS from a normally sterile site or 2) diagnostic codes related to substance use and a bacterial or fungal pathogen or infection† were included. Injection drug use was defined as patient self-report of injection drug use; health care worker, relative, or friend report that the person injected drugs; or observation of injection equipment in the patient’s room or belongings or skin lesions indicative of injection drug use (track marks). Demographic information, infection sites, bacterial and fungal pathogens, history of human immunodeficiency virus (HIV), hepatitis B and C, and clinical outcomes were abstracted from medical records for all patients with injection drug use. Information on substance use history and treatment was collected for a subset of persons whose infections were identified from S. aureus, Candida spp., or GAS culture. A chi-squared test was performed using SAS (version 9.4; SAS Institute) to compare the proportion of patients seen only in the ED to the proportion of hospitalized patients who were offered medication-assisted treatment. To assess the sensitivity of identifying patients with infections using diagnostic codes alone, the proportion of patients who injected drugs identified by positive cultures who also had diagnostic codes for both substance use and a bacterial or fungal pathogen or infection was calculated.
Among 1,002 patients who met either inclusion criterion, medical records for 111 (11%) documented injection drug use during the previous 12 months. The median age of these persons was 32 years (range = 18–68 years); 61% were women (Table). Skin and soft tissue infections accounted for 82 (74%) infections, and endocarditis accounted for 16 (14%). Among skin and soft tissue infections, 50 (61%) were documented to be at an injection site, and 12 (15%) were not at an injection site. For 20 patients (24%), the medical record did not document whether the infection was at a site where the person injected drugs. Overall, 79 persons (71%) were hospitalized, of whom 19 (24%) were hospitalized for ≥30 days. Four (4%) patients died before leaving the hospital. Thirty-three (30%) patients left the hospital against medical advice, including 13 (41%) of 32 persons seen only in the ED and 20 (25%) of 79 persons admitted to the hospital.
Of 70 patients with at least one pathogen identified from a clinical culture, 13 (19%) had a polymicrobial infection. The most common bacterial and fungal pathogens were S. aureus (56; 80%); streptococci (11; 16%), including eight viridans group and two GAS; and Candida spp. (4; 6%). The most common bloodborne pathogen identified§ was hepatitis C virus; 41 (37%) patients had a current or previous hepatitis C virus infection documented in the medical record; seven (6%) had a history of HIV infection, and four (4%) had hepatitis B virus infection.
Among a subset of 59 (53%) patients with S. aureus, Candida spp., or GAS infections from whom drug use data were collected, 57 (97%) used opioids, including 50 who injected opioids and seven with an unknown route of opioid administration. Among 44 inpatients, 22 (50%) were offered medication-assisted treatment for opioid use disorder, whereas one of 13 (8%) persons seen only in the ED was offered medication-assisted treatment (p-value = 0.01). Most patients with an infection identified by culture (74%) also had diagnostic codes for both substance use and an infection or pathogen.
Discussion
On average, at least one person with a bacterial or fungal infection who also injects drugs visited one of the five assessed hospitals every day during the analysis period. This investigation highlights the importance of preventing opioid misuse, treating opioid use disorder, and emphasizing the risks of bacterial and fungal infections as well as bloodborne pathogens during care of persons who inject drugs. In this assessment, infections related to injection drug use most often occurred at the site of injection and were predominantly caused by common skin and mouth flora that are introduced during injection. Infections related to injection also included invasive infections, such as endocarditis. Many of the infections required prolonged hospital stays, with 24% of patients hospitalized for at least 30 days. Although nearly all patients injected opioids, many were not offered medication-assisted treatment for opioid use disorder. Those seen only in the ED were less likely to be offered medication-assisted treatment than inpatients.
This assessment was limited to western New York; however, bacterial and fungal infections might also occur frequently in other communities in the United States. Although the prevalence of injection drug use is unknown, the age-adjusted rate of overdose deaths involving any drug in Monroe County, New York, where four of the five hospitals were located, was 24.5 per 100,000 residents in 2016,¶ compared with 19.8 drug overdose deaths per 100,000 residents for the United States as a whole (6).
The findings in this report are subject to at least three limitations. First, the number of bacterial and fungal infections among persons who inject drugs was likely underestimated because the data did not include outpatient visits or infections in persons who did not seek health care. Second, medical records do not always specify the route of drug administration; records indicating that the patient used drugs but did not document injection were excluded, which also might underestimate the number of persons injecting. Finally, the method of identifying infections could bias the distribution of pathogens or infection types. S. aureus, Candida spp. and GAS infections were identified by both culture and diagnostic codes. Infections with other pathogens or without a pathogen identified were identified by diagnostic codes only, and therefore were more likely to be missed. However, evidence suggests that most infections were identified through diagnostic codes. Among S. aureus, Candida spp., and GAS infections identified by culture, 74% had codes for both an infection syndrome and substance use.
Routine care for patients who continue to inject should include advice on hand hygiene and not injecting into skin that has not been cleaned or to use any equipment contaminated by reuse, saliva, soil, or water (4,5). Risk factors for bacterial and fungal infections found in other recent assessments include skin breakdown and limited access to clean running water and showers (7). Where legal, syringe service programs can provide referrals to treatment for substance use disorder, clean equipment, and education about safer injection practices. Other services, such as prompt wound care, laundry, and showers could also help prevent serious bacterial and fungal infections (8). Because some persons who misuse prescription opioids transition to injecting opioids, primary prevention strategies that can reduce the risk for opioid misuse and potential subsequent infection from unsafe injection practices include appropriate opioid prescribing practices and efforts to ensure access to nonopioid treatments for pain (9). Medication-assisted treatment addresses the underlying opioid use disorder through decreased cravings and prevents infections by reducing injection drug use. Initiating medication-assisted treatment when persons who inject opioids are found to have a bacterial or fungal infection might also improve retention of these patients in treatment for both the infection and substance abuse (10). Hospitalizations and ED visits for these infections are opportunities to link patients to treatment for opioid use disorder and prevent recurrent infections.
Acknowledgments
Sanuja Bose, Peter Joo, Daniel Underberg, Holden Wagstaff, University of Rochester Medical Center, Rochester, New York; Lacey Gleason, Julian Grass, Hannah Reses, Christina Sancken, Shirley Zhang, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC; Snigdha Vallabhaneni, Sabrina Williams, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC; Anita Gellert, Trupti Hatwar, Zeina Naoum, New York Emerging Infections Program; staff members from New York hospitals.
Corresponding author: Kathleen P. Hartnett, khartnett@cdc.gov, 404-718-6790.
1Epidemic Intelligence Service, CDC; 2Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC; 3Emerging Infections Program, University of Rochester Medical Center, Rochester, New York; 4New York State Department of Health; 5Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC; 6Monroe County Department of Public Health, New York; 7Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, CDC; 8Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC; 9Office of Policy, Planning and Partnerships, Office of the Director, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC.
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. Elizabeth Dufort reports that her spouse has a Gilead Foundation FOCUS research grant for expanded hepatitis C virus screening and testing. No other potential conflicts of interest were disclosed.
* https://idsa.confex.com/idsa/2018/webprogram/Paper72151.html.
† Infection and substance use related codes: A18.84, A31*, A32.82, A39*, A39.51, A41*–A44*, A46*, A48*, A49*, A54.83, B37* –B46*, B49, B95*–B96*, B99.8*, B99.9*, D73.3, E06.0, E32.1, G06*, H05*, I08, I33*, I38, I39, I40.0, I51.89, 172.9, I76, I80*, I96, J85*, J86*, K11.3, K12.2, K13.0, K61*, K65*, K68.1*, L01*–L04*, L08*, L97*, L98.4*, M00*, M01*, M27.2, M46.2*, M46.3*–M46.5, M65.0*, M71.0*, M72.6, M72.8, M86*, N15.1, R65.2*, R78.81, T79.8XXA, T80.2*, Z16, Z79.2. ICD-10 substance use related codes: F11*, F13*–F16*, F18*, F19*, T40*.
§ Hepatitis B virus (HBV), hepatitis C virus (HCV), HIV chronic or acute infection noted in the medical history, or the patient had 1) positive HBV surface antigen, 2) positive HCV antibody without RNA tested (could indicate resolved or cured infection) or detectable HCV viral load, or 3) positive HIV test in the record.
¶ New York State Opioid Dashboard. https://www.health.ny.gov/statistics/opioid.
References
- Jackson KA, Bohm MK, Brooks JT, et al. Invasive methicillin-resistant Staphylococcus aureus infections among persons who inject drugs—six sites, 2005–2016. MMWR Morb Mortal Wkly Rep 2018;67:625–8. CrossRef PubMed
- Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014;2:CD002207. CrossRef PubMed
- Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017;357:j1550. CrossRef PubMed
- Murphy EL, DeVita D, Liu H, et al. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin Infect Dis 2001;33:35–40. CrossRef PubMed
- Asher AK, Zhong Y, Garfein RS, Cuevas-Mota J, Teshale E. Association of self-reported abscess with high-risk injection-related behaviors among young persons who inject drugs. J Assoc Nurses AIDS Care 2019;30:142–50. CrossRef PubMed
- Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. MMWR Morb Mortal Wkly Rep 2018;67:349–58. CrossRef PubMed
- Barter DM, Johnston HL, Williams SR, Tsay SV, Vallabhaneni S, Bamberg WM. Candida bloodstream infections among persons who inject drugs—Denver metropolitan area, Colorado, 2017–2018. MMWR Morb Mortal Wkly Rep 2019;68:285–8. CrossRef PubMed
- Grau LE, Arevalo S, Catchpool C, Heimer R. Expanding harm reduction services through a wound and abscess clinic. Am J Public Health 2002;92:1915–7. CrossRef PubMed
- Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep 2016;65(No. RR-1). CrossRef PubMed
- Marks LR, Munigala S, Warren DK, Liang SY, Schwarz ES, Durkin MJ. Addiction medicine consultations reduce readmission rates for patients with serious infections from opioid use disorder. Clin Infect Dis 2019;68:1935–7. CrossRef PubMed
Abbreviations: ED = emergency department; Q1 = quartile 1; Q3 = quartile 3.
* April 1–June 30, 2017, at five hospitals in western New York for patients of any age who injected drugs and had 1) positive cultures for S. aureus (excluding nasal specimens), Candida spp. in blood, or group A Streptococcus from a normally sterile site or 2) diagnostic codes including both substance use disorder and a bacterial or fungal pathogen or infection.
† Percentages are calculated among 70 patients with an organism identified and do not sum to 100 because 13 of 70 persons (19%) had an infection with more than one organism identified.
§ 30 methicillin-resistant S. aureus and 26 methicillin-sensitive S. aureus.
¶ Eight viridans group Streptococcus, two group A Streptococcus, and one group C Streptococcus.
** 12 gram-negative bacteria including Enterobacter cloacae (two), Eikenella corrodens, Escherichia coli, Leclercia spp., Moraxella catarrhalis, Serratia marcescens, Sphingomonas paucimobilis, unspecified gram-negative rods (three), unspecified anaerobic gram-negative cocci; 10 gram-positive bacteria including Actinomyces spp. (two), coagulase negative Staphylococcus (two [possible contaminants]), Aerococcus viridans, Bacillus spp., Corynebacterium spp., Granulicatella spp., unspecified gram-positive cocci chain, and unspecified gram-positive bacilli.
†† Infection types are not mutually exclusive, with the exception of bacteremia without other infection type, and other, which includes only patients without another infection type. Other includes intra-abdominal abscess, supraclavicular lymphadenitis, spontaneous bacterial peritonitis, and subacute fungal cerebritis with meningoencephalitis.
§§ Includes necrotizing fasciitis (two). Among 82 skin and soft tissue infections, 50 (61%) were documented in the medical record to be at a known injection site, 12 (15%) were not at an injection site, and for 20 (24%), it was unknown or not documented whether the infection was at an injection site.
¶¶ Patients for whom drug use data were collected.
*** Chronic infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) noted in the medical history, or the patient had 1) positive HBV surface antigen, 2) positive HCV antibody without RNA tested (could indicate resolved or cured infection) or detectable HCV viral load, or 3) positive HIV test in the record.
††† Excludes six patients without diagnostic codes available for review in the medical record.
Suggested citation for this article: Hartnett KP, Jackson KA, Felsen C, et al. Bacterial and Fungal Infections in Persons Who Inject Drugs — Western New York, 2017. MMWR Morb Mortal Wkly Rep 2019;68:583–586. DOI: http://dx.doi.org/10.15585/mmwr.mm6826a2.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.
References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.